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apoptosis (TWEAK) and its receptor, ﬁbroblast growth
factor-inducible 14 (Fn14), mediate inﬂammation and neu-
ronal apoptosis in cerebral edema, ischemic stroke and mul-
tiple sclerosis. The downstream eﬀectors and pathways
linked to TWEAK–Fn14 signaling are strongly implicated in
the pathology of Parkinson’s disease (PD), thus indicating
a putative role for TWEAK/Fn14 signaling in PD neurodegen-
eration. Using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri
dine (MPTP) mouse model, we aimed to determine whether
genetic ablation or pharmacologic mitigation of the TWEAK
protein and its Fn14 receptor aﬀected substantia nigra and
striatum Parkinsonian pathology. Changes in endogenous
TWEAK protein expression were also quantiﬁed in tissue
from both MPTP-treated mice and PD human sam-
ples. TWEAK protein expression was transiently increased
in the striatal tissue but remained unaltered in substantia
nigra tissue of MPTP-treated mice. There was also no
change of TWEAK protein levels in the substantia nigra or
the striatum of human PD patients as compared to matched
control subjects. Mitigating the eﬀects of endogenous
TWEAK protein using neutralizing antibody did aﬀect
MPTP-mediated neurotoxicity in the substantia nigra using
the sub-acute model of MPTP (30 mg/kg i.p. over ﬁvehttp://dx.doi.org/10.1016/j.neuroscience.2016.01.034
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116consecutive days). Neither TWEAK nor Fn14 genetic abla-
tion led to attenuation of MPTP-toxicity in the acute
model. These ﬁndings suggest that TWEAK signaling
might be an aspect of MPTP-mediated neuropathology and
be involved in the overall neurodegenerative pathology of
PD.  2016 The Authors. Published by Elsevier Ltd. on
behalf of IBRO. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
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INTRODUCTION
Parkinson’s disease (PD) is one of the main
neurodegenerative disorders and is symptomatically
characterized by debilitating movement impairments.
The main underlying pathology of PD is the degeneration
of dopaminergic neurons in the nigrostriatal pathway.
Systemic administration of the neurotoxin 1-methyl-4-phe
nyl-1,2,3,6-tetrahydropyridine (MPTP) causes a similar
nigrostriatal-selective dopaminergic cell loss in the
mouse brain and therefore provides a suitable animal
model to study PD neuropathology. Mechanisms such
as microglial activation, oxidative stress and
inﬂammatory cytokine release can mediate dopaminergic
cell loss and their roles in PD neuropathology have been
studied using the MPTP model (Litteljohn et al., 2010).
Members of the tumor necrosis factor (TNF)
superfamily of inﬂammatory cytokines have been shown
to be up-regulated in the substantia nigra (Boka et al.,
1994) and the striatum (Mogi et al., 1994) of post-
mortem brains of PD patients. Also, genetic deﬁciency
of TNF-alpha signaling can confer neuroprotection
against MPTP neurotoxicity in mice (Sriram et al., 2002;
Ferger et al., 2004). One of the main apoptotic down-
stream eﬀectors linked with TNF superfamily-related
signaling in neuronal cells is the nuclear factor kappa-
light-chain-enhancer of activated B cells (NFjB) signal
transduction pathway (Aggarwal, 2003). NFjB nuclear
translocation and activation mediates apoptotic eﬀects
via the tumor suppressor protein p53 (Ryan et al.,
2000). In accordance with this concept, cultured dopamin-
ergic neurons exposed to excitotoxic insult undergo apop-
tosis that is linked to NFjB-p53 signaling (de Erausquin
et al., 2003). In the substantia nigra of PD patients, NFjB
nuclear content is increased speciﬁcally in the remaining
dopaminergic neurons indicating that the NFjB signal
transduction pathway is relevant to PD neuropathology/licenses/by/4.0/).
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MPTP model (Dehmer et al., 2004). On the other hand
we have to keep in mind that ablation of c-Rel leads to
a late on-set of Parkinson-like features indicating a possi-
ble dual role – protective/promoting neurodegeneration of
NF-jB (Baiguera et al., 2012).
More recently characterized members of the TNF
superfamily include the TNF-like weak inducer of
apoptosis (TWEAK) and its ﬁbroblast growth factor-
inducible 14 (Fn14) receptor (Chicheportiche et al.,
1997; Wiley et al., 2001). TWEAK is a soluble cytokine
widely expressed in neurons, astrocytes and macro-
phages and it acts as a ligand for the Fn14 receptor, the
expression of which is up-regulated after tissue injury,
including in injured hepatic, vascular and neuronal cells,
and in tumors (Desplat-Jego et al., 2005; Winkles,
2008). TWEAK–Fn14 signaling has been linked to NFjB
nuclear translocation and signal transduction (Brown
et al., 2003; Tran et al., 2005). Furthermore, NFjB con-
trols transcription of the gene for cycoloxygenase-2
(COX-2) which underlies PD neuropathology as demon-
strated in the MPTP mouse model and observed in
human PD tissue (Teismann et al., 2003). Thus, pro-
inﬂammatory cytokines such as TWEAK can activate
NFjB and its transcriptional control of downstream
inﬂammatory mediators such as COX-2 and can therefore
initiate and/or further exacerbate the neuroinﬂammatory
and degenerative processes.
Neuronal death and neuroinﬂammatory processes
have long been implicated in the pathogenesis of PD.
Substantial evidence demonstrates that TWEAK–Fn14
signaling mediates neuroinﬂammatory processes and
apoptotic cell death in in vitro and in vivo models of
cerebral edema, ischemic stroke and multiple sclerosis
(reviewed by Yepes (2007)). In models of pathological
conditions such as ischemic stroke, chronic injury is asso-
ciated with up-regulation of TWEAK and Fn14 expression
(Potrovita et al., 2004; Inta et al., 2008). The neuronal cell
death observed in these in vivo ischemia models, as well
as in primary culture of cortical neurons undergoing oxy-
gen–glucose deprivation, is associated with the observed
increase in TWEAK and subsequent binding to Fn14 and
activation of NF-jB expression (Potrovita et al., 2004;
Polavarapu et al., 2005). Additionally it was shown, that
the observed increase in the expression of monocyte
chemoattractant protein-1 (MCP-1) and the recruitment
of neutrophils after middle cerebral artery occlusion was
absent in TWEAK/ and Fn14/ mice (Haile et al.,
2010). Reactive microglia and astrocytes mediate inﬂam-
mation processes that contribute to the neurodegenera-
tive process in PD (Hirsch et al., 1999; Teismann and
Schulz, 2004) and TWEAK has been shown to act on
and mediate pro-inﬂammatory cytokine expression in
astrocytes (Saas et al., 2000).
To date, little is known about the involvement of the
TWEAK Fn-14 signaling complex in PD neurode-
generation. The aim of the present study is to determine
the role of TWEAK–Fn14 in PD neuropathology as
modeled using the MPTP neurotoxin in mice. We
observed the eﬀect of genetic ablation of TWEAK and
Fn14 and neutralizing of TWEAK on MPTP-mediatedneuropathologies such as dopaminergic cell loss in the
substantia nigra, as well as dopamine depletion and ﬁber
degeneration in the striatum.
EXPERIMENTAL PROCEDURES
Animals and treatment
Mice engineered with knockout of TWEAK or Fn14 (i.e.
TWEAK/ and Fn14/) (Biogen Idec, Inc., Cambridge,
MA, USA) (Jakubowski et al., 2005; Girgenrath et al.,
2006), and wild-type littermates received an acute MPTP
regime (4  18 mg/kg, intraperitoneal injections (i.p.), 2 h
apart over one day). Mice were sacriﬁced 7 days after
MPTP administration and their brain tissue was collected
and processed for substantia nigra and striatal tyrosine
hydroxylase (TH) immunohistochemistry and striatum
monoamine high-performance liquid chromatography
(HPLC) measurements.
For the neutralizing antibody experiments, adult male
wild-type C57BL/6 mice weighing 20–25 g (Charles River
Laboratories, Ormiston, UK) were treated with either an
acute (4  18 mg/kg, i.p., 2 h apart) or sub-acute regimen
of MPTP (5  30 mg/kg, i.p., over ﬁve consecutive days)
and were injected i.p. with 200 lg anti-mouse TWEAK
neutralizing antibody (Biogen Idec, Inc.) or isotype
control antibody (Biogen Idec) 30 min prior to MPTP
treatment (Potrovita et al., 2004). In the latter study the
authors showed that the antibody crosses the blood–brain
barrier. For striatum monoamine HPLC measurements
and substantia nigra and striatal TH immunohistochem-
istry, mice undergoing the acute MPTP-regimen were
killed 7 days after MPTP injection, mice undergoing the
sub-acute MPTP-regimen 21 days after MPTP injection.
For endogenous TWEAK protein expression
experiments, adult male wild-type C57BL/6 mice
weighing 20–25 g (Charles River Laboratories, Ormiston,
UK) were treated with an acute regime of MPTP
(4  18 mg/kg, i.p., 2 h apart). Control mice received
saline-vehicle. Sub-groups of mice were sacriﬁced at
various time points following MPTP administration (0, 1,
2, 4, 7, 14 and 21 days). All procedures complied with
the European Community Council Directive (2010/63/UE)
and the Animals (Scientiﬁc Procedures) Act 1986 and
were approved by the Home Oﬃce or the
Regierungspra¨sidium Karlsruhe, Germany. Mice were
housed in appropriately sized cages with access to food
and water ad libitum, with a 12-hour light–dark cycle
(lights on at 7 am).
Human samples
Human nigral tissue was obtained from the UK
Parkinson’s Disease Tissue Bank at Imperial College,
London. Selected PD patients and controls were
matched for age at death. Controls were (n= 5) 80.4
± 2.66 years at death (mean ± SEM) and PD patients
(n= 6) 79 ± 2.02 years with an average disease
duration of 9.08 ± 1.20 years (mean ± SEM). The age
at onset of disease seen was 69.83 ± 2 years. None of
the PD patients had a family history of the disease.
Samples were isolated in NP-40 buﬀer with protease
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were centrifuged at 14,000 rpm (18,620g; Mikro 200R)
for 20 min at 4 C and supernatants retained. All
procedures were approved by the responsible ethics
committee (North of Scotland Research Ethics
Committees).Western blot analysis
The midbrain and striatum were dissected out from the
mouse brain; total protein was isolated in ice-cold NP-40
buﬀer (20 mM Tris, 137 mM NaCl, 10% glycerol, 1%
NP-40, 2 mM EDTA). The protein concentration was
assessed using bicinchoninic acid (BCA) assay kit
(Pierce, Rockford, IL, USA). 20 lg of protein (in
Laemmli buﬀer and mercaptoethanol) was loaded onto a
12% SDS–polyacrylamide gel (SDS–PAGE) and
transferred to a nitrocellulose membrane. After blocking
with 5% milk powder in phosphate-buﬀered saline (PBS)
containing 0.05% Tween-20 for 1 h the blots were
incubated with the following primary antibodies: TWEAK
(1:500, Cell Signalling) and b-actin (1:25,000, Sigma–
Aldrich, UK) at 4 C overnight, then rinsed with 0.05%
PBS-Tween followed by an incubation at room
temperature for 1 h with a horseradish peroxidase
(HRP)-conjugated secondary antibody (anti-rabbit or
anti-mouse 1:10,000, Amersham). After washing in
PBS-Tween the blots were exposed to a homemade
ECL solution (Luminol sodium salt in 0.1 mM Tris HCl
and Para-hydroxycoumarin in DMSO) for 1–2 min and
then viewed in the Alpha Imager and quantiﬁed using
the Alpha imaging software.
Using the above protocol Western blot analysis was
also performed on post mortem human brain samples.Immunohistochemistry studies
Mouse brains were dissected out and ﬁxed in 4%
paraformaldehyde (overnight at 4 C) and then
transferred to 30% (w/v) sucrose solution. The brains
were then frozen by immersion in isopentane and stored
at 80 C. Coronal sections of frozen brains were cut
(30 lm) in a cryostat. Ventral midbrain and striatal
sections were collected in PBS with 0.01% sodium
azide. The sections were washed with Tris-buﬀered
saline (TBS) (three times for 5 min each), incubated with
10% methanol and 3% hydrogen peroxide, washed with
TBS; incubated for 1 h in 5% normal goat serum
followed by an incubation for 48 h with primary TH
antibody (1:1000), rinsed with TBS (three times for
5 min each) and then incubated with biotinylated anti
rabbit (1:200, Vector labs) antibody. After washes in
PBS (three times for 5 min each) the sections were
incubated for 1 h in HRP–avidin biotin complex (Vector),
followed by washes in PBS (three times for 5 min each)
and incubated for 15 min in diaminobenzidine (in 0.1 M
Tris–HCl, pH = 7.6). All the sections were then
mounted and dehydrated, counterstained with Nissl
before viewing under a brightﬁeld microscope. TH- and
Nissl-positive cell counts in the substantia nigra pars
compacta (SNpc) were quantiﬁed and estimated using
the optical fractionator method (Stereoinvestigator,Microbrightﬁeld Bioscience, Magdeburg, Germany) at
100 magniﬁcation. Striatal ﬁber staining was quantiﬁed
by comparing the average optical density (AOD) of
staining in the striatum with the surrounding cortical
tissue, using Scion Image software.HPLC analysis of striatal monoamine levels
HPLC with electrochemical detection was used to
measure striatal levels of dopamine, DOPAC and
serotonin using a method that has been described
(Sathe et al., 2012; Nuber et al., 2008). Brieﬂy, after mice
were killed, striata were dissected out and snap frozen
directly on dry ice. Striata were then homogenized in
1% perchloric acid (PCA) (1:30 [i.e. tissue weight: PCA
volume]) and centrifuged at 14,000g at 4 C for 20 min.
Following centrifugation, 20 ll of the supernatant sample
was injected onto a C18 column (Dionex, Germering,
Germany). The mobile phase consisted of 90% 50 mM
sodium acetate, 35 mM citric acid, 105 mg/L octane sul-
fonic acid, 48 mg/L sodium EDTA solution, and 10%
methanol at pH 4.3. Flow rate was 1 ml/min. Peaks were
detected by an ESA Coulochem II electrochemical detec-
tor (ESA), and the detector potential was set at 700 mV.
Data were collected and processed using the Chromeleon
computer system (Dionex).Statistical analysis
All values expressed are mean ± the standard error of
the mean (SEM). Diﬀerences between means were
analyzed using Student’s t-test. Diﬀerences among
means were analyzed using a one-way ANOVA. When
ANOVA showed signiﬁcant diﬀerences, pair-wise
comparisons between means were assessed using the
Newman–Keuls post hoc test. Null hypothesis was
rejected at 0.05 levels. All analysis was performed using
SPSS for windows and Graphpad Prism softwares.RESULTS
TWEAK protein expression in the acute MPTP model
and human PD samples
To determine the expression pattern of TWEAK, we
looked at the protein levels of TWEAK in the ventral
midbrains and striata of saline and MPTP-treated mice
at diﬀerent time points. No change in nigral protein
levels of TWEAK was seen in acute MPTP-treated mice
when compared to saline at any of the various time
points after MPTP treatment (p> 0.05, ANOVA with
Newman–Keuls post-hoc, Fig. 1A). However, an
increase was seen in striatal levels of TWEAK protein
on 2, 4 and 7 days after treatment with MPTP
(p= 0.03, compared to saline, ANOVA with Newman–
Keuls post-hoc, Fig. 1B).
The protein expression levels for TWEAK were also
quantiﬁed in post-mortem human control and PD
samples. No change was seen in TWEAK expression in
either substantia nigra (Fig. 1C) or striatal (Fig. 1D)
tissue of PD patients when compared to extracts from
control human tissue.
Fig. 1. Protein expression of TWEAK in acute MPTP-treated mice and PD human samples. Western blot analysis of TWEAK protein levels
normalized against b-actin levels in (A) SNpc and (B) striatal tissue extracted at various time points after acute MPTP treatment in mice. No change
in protein levels of TWEAK was seen in the SNpc (A), however an increase in TWEAK expression is seen in the striatum (B) on days 2, 4, and 7 after
MPTP treatment (n= 4–6; *P< 0.05, compared with saline-treated animals [S], ANOVA with Newman–Keuls post-hoc test). Western blot analysis
of TWEAK protein levels normalized against b-actin levels in (C) SNpc and (D) striatal tissue samples obtained from post-mortem human PD
patients and control subjects. No change in protein expression was found in either the SNpc or striatum of post-mortem human PD samples.
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acute MPTP toxicity
According to HPLC analysis, TWEAK and Fn14 ablation
had no signiﬁcant eﬀect on levels of dopamine in the
striatum compared to their wild-type counterparts
(Table 1).
In the SNpc, the number of TH- and Nissl-positive
dopaminergic neurons in acute MPTP-treated
TWEAK/ or Fn14/ mice did not show any changes
when compared to wild-type MPTP-treated mice
(Table 1). Striatal TH-immunoreactivity appeared to be
reduced in TWEAK/ mice in response to MPTP as
compared to wild-type MPTP-treated mice, however, the
eﬀect was not signiﬁcant (Table 1). Thus, genetic
ablation of TWEAK/ or Fn14/ does not attenuate
the eﬀect of acute MPTP on SNpc dopaminergic cell
counts and striatal dopaminergic ﬁber density.
Neutralizing TWEAK mitigates eﬀects of sub-acute
MPTP on nigral dopaminergic neurons
Having established that TWEAK levels in the striatum are
altered by MPTP treatment (Fig. 1B), we assessed
whether neutralization of TWEAK had an eﬀect on
MPTP-induced cell death. Neutralizing TWEAK did not
lead to a change in SNpc cell counts of TH-positivedopaminergic neurons in mice dosed with acute MPTP
at 18 mg/kg (Fig. 2 and Table 1) or at a lower MPTP
dose of 16 mg/kg (data not shown) when compared to
cell counts from mice that had received MPTP alone.
Using the less severe sub-acute regimen signiﬁcantly
more dopaminergic neurons survived after MPTP-
induced cell death in mice receiving the TWEAK
antibody compared to controls treated with the isotype
control Ig (Fig. 2 and Table 1).
In HPLC analysis we did observe higher striatal
dopamine levels caused by neutralizing TWEAK
antibody treatment combined with MPTP although not
signiﬁcant (Table 1).DISCUSSION
Using both genetic knockout and neutralizing antibody
methods, we aimed to determine whether TWEAK–Fn14
signaling is involved in MPTP-induced eﬀects in the
substantia nigra (SN) and striatum of mice. We also
measured TWEAK protein expression in substantia
nigra and striatal tissue from MPTP-treated mice and
PD patients. Our results show that TWEAK-neutralizing
antibody leads to attenuation of MPTP-induced
dopaminergic cell death in the SNpc.
Table 1. Eﬀects of TWEAK/Fn14 manipulation on MPTP-induced toxicity
Dopamine (ng/mg wet
tissue weight)
TH-positive neurons in
the SNpc
Nissl cells in the
SNpc
TH-positive ﬁbers in the striatum
(o.d. * 100)
Saline
wt 11.367 ± 1.045 10790 ± 293 11370 ± 459 4.464 ± 0.619
FN14/ 11.898 ± 1.140 9370 ± 138 10095 ± 1380 4.512 ± 0.249
TWEAK/ 11.655 ± 1.095 9800 ± 637 10215 ± 465 4.630 ± 0.204
Scrambled antibody 12.246 ± 1.210 10475 ± 1863 10867 ± 845 4.850 ± 0.251
TWEAK antibody 11.624 ± 1.445 10380 ± 1894 9333 ± 1244 4.417 ± 0.590
MPTP
wt 2.196 ± 0.266 4087 ± 556 4740 ± 392 0.0178 ± 0.097
FN14/ 2.596 ± 0.597 3687 ± 493 4730 ± 400 0.0179 ± 0.090
TWEAK/ 2.911 ± 0.439 3440 ± 810 4980 ± 539 0.0141 ± 0.071
Scrambled antibody acute
MPTP
1.968 ± 0.449 3090 ± 530 4478 ± 172 0.030 ± 0.005
TWEAK antibody acute
MPTP
1.534 ± 0.280 3464 ± 639 4387 ± 167 0.0233 ± 0.007
Scrambled antibody sub-
acute MPTP
3.029 ± 0.355 5983 ± 269 7733 ± 473 0.030 ± 0.005
TWEAK antibody sub-acute
MPTP
4.361 ± 0.753 7337 ± 454* 8410 ± 460 0.0233 ± 0.007
Values are mean ± SEM for six mice/group. Dopamine content was assessed by HPLC. Neuron and cell count were performed with stereology. Density of tyrosine
hydroxylase (TH)-positive ﬁbers was assessed by use of ScionImage Scion Corp., Frederick, Maryland, USA), and calculated using the formula: mean o.d. * 100.
* P< 0.05 compared to numbers of TH-positive neurons in the SNpc in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-injected mice receiving scrambled antibody
under the sub-acute regimen (Bonferroni post-hoc test).
Fig. 2. Eﬀect of TWEAK neutralizing antibody on MPTP toxicity. Numbers of TH-positive neurons in the SNpc are comparable between saline-
treated mice receiving TWEAK-neutralizing antibody and isotype control Ig (upper panel, Table 1). Three weeks after acute MPTP treatment,
numbers of TH-positive neurons are not signiﬁcantly diﬀerent between mice receiving isotype control Ig or TWEAK neutralizing antibody (middle
panel, Table 1); whereas after sub-acute MPTP-treatment mice initially receiving also TWEAK-neutralizing antibody treatment show higher numbers
of TH-positive neurons, than do mice who received isotype control Ig (lower panel, Table 1). Striatal optical density was comparable between saline-
treated mice receiving TWEAK-neutralizing antibody and isotype control Ig (upper panel, Table 1). Treatment with TWEAK neutralizing antibody had
no eﬀect on MPTP-induced loss of striatal optical density in the acute (middle panel, Table 1) or sub-acute (lower panel, Table 1) model. Pictures of
SNpc at 2.5 magniﬁcation and inlay at 40 magniﬁcation. Pictures of striatum at 1 magniﬁcation, with inlay at 40 magniﬁcation.
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signiﬁcant diﬀerences in TWEAK protein levels were
observed between PD patients vs. healthy controls and
MPTP-treated mice vs. saline-treated mice. However, in
striatal tissue of MPTP-treated mice, there was
increased TWEAK protein levels detected 2 days after
treatment. This increase in striatal TWEAK protein was
detected also on days 4 and 7 after MPTP-treatment. In
post-mortem human striatal tissue from PD patients, we
observed a trend of increased TWEAK protein in
comparison to healthy controls, which if it were a
statistically signiﬁcant eﬀect would have mimicked the
transient striatal TWEAK expression seen in the mouse
MPTP model. The expression levels of TWEAK and
Fn14 proteins were also measured in human cortex
samples obtained from healthy controls and PD patients
with PINK and IPD mutations (data not shown). There
was no diﬀerence in protein expression of either
TWEAK or Fn14 between controls and the hereditary
mutation samples suggesting that TWEAK and Fn14
expression changes are not associated with these
hereditary forms of the disease and/or are not observed
in the cortex.
It is interesting to observe at ﬁrst view that TWEAK
antibody is able to protect nigral dopaminergic neurons
partially against MPTP-toxicity, whereas TWEAK as well
as Fn14 ablation fails to provide any signiﬁcant beneﬁt.
Diﬀerent factors need to be kept in mind, which could
have contributed to the observed diﬀerences. First of all,
in the antibody study, a sub-acute regimen of MPTP
administration was used. This model is linked closer to
apoptotic induced cell death (Tatton and Kish, 1997), than
the acute model, where cell death occurs mainly via
necrosis (Jackson-Lewis et al., 1995). Another possibility
could be that ablation of TWEAK or Fn14 leads to com-
pensatory mechanisms, which then result in the observed
eﬀect, or anti-TWEAK resulted in Fc-mediated killing of
TWEAK-expressing neuroinﬂammatory cells such as
microglia.
Although we did not investigate glial activation in this
study, it is interesting to note that TWEAK has been
shown to be expressed in glial cells and has been
reported to induce apoptosis by interacting with
endogenous TNF-a and TNF receptor 1 (TNFR1)
(Schneider et al., 1999). TNF-a expression in microglial
cells has been shown in PD patients (Hunot et al.,
1999). It has been demonstrated that TNFR1 ablation
leads to neuroprotection in the MPTP-model of PD, sug-
gesting the participation of TNF-a via TNFR1 in MPTP-
induced cell death and in PD (Sriram et al., 2002;
Ferger et al., 2004). As TNF-a and TNFR1 factors are
mainly involved in apoptotic cell death, perhaps TWEAK
as well as Fn14 ablation did not result in neuroprotection
in the acute MPTP-model since cell death in the acute
model mainly occurs via necrosis (Jackson-Lewis et al.,
1995). Although a TWEAK antibody did provide partial
neuroprotection in the sub-acute model, it was not a sub-
stantial protection, indicating, that the cell death pro-
cesses in the MPTP-model are not mainly triggered via
TWEAK. Although, TWEAK has been shown to interact
with TNF-a, this seems not to be the main case in theMPTP-model. Also, we did not ﬁnd a signiﬁcant increase
of TWEAK in the SNpc of PD patients.
Taking together our data suggest a minor role for
TWEAK in PD. Still, when generating a neuroprotective
therapy for the treatment of PD, one should keep in
mind the potential role of TWEAK, and it might still
prove to be a useful in a multi-target therapy, which in
the end could be the way forward for the treatment of
this debilitating disorder.
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